For example, nintedanib treating idiopathic pulmonary fibrosis can reduce the expression of proinflammatory factors IL-1β, IL-6, and TNF-ɑ by downregulating the PI3K/Akt/mTOR pathway [51]. This evidence concerns the gene IL1B and pulmonary fibrosis.